Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis

被引:58
|
作者
Ahluwalia, Vishwadeep [1 ,2 ,3 ]
Heuman, Douglas M. [1 ,2 ]
Feldman, George [2 ,4 ]
Wade, James B. [2 ,5 ]
Thacker, Leroy R. [2 ,6 ]
Gavis, Edith [1 ,2 ]
Gilles, HoChong [1 ,2 ]
Unser, Ariel [1 ,2 ]
White, Melanie B. [1 ,2 ]
Bajaj, Jasmohan S. [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Dept Gastroenterol Hepatol & Nutr, Richmond, VA 23221 USA
[2] McGuire VA Med Ctr, Richmond, VA 23221 USA
[3] Virginia Commonwealth Univ, Dept Radiol, Richmond, VA 23221 USA
[4] Virginia Commonwealth Univ, Dept Nephrol, Richmond, VA 23221 USA
[5] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23221 USA
[6] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23221 USA
关键词
Caregiver burden; Aquaresis; Diffusion tensor imaging; Hepatic encephalopathy; Magnetic resonance spectroscopy; Tolvaptan; HEPATIC-ENCEPHALOPATHY; VASOPRESSIN ANTAGONIST; HEALTH; HYPERAMMONEMIA; TOLVAPTAN; BURDEN;
D O I
10.1016/j.jhep.2014.07.033
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Hyponatraemia in cirrhosis is associated with impaired cognition and poor health-related quality of life (HRQOL). However, the benefit of hyponatraemia correction is unclear. The aim of this study was to evaluate the effect of tolvaptan on serum sodium (Na), cognition, HRQOL, companion burden, and brain MRI (volumetrics, spectroscopy, and diffusion tensor imaging) in cirrhotics with hyponatraemia. Methods: Cirrhotics with Na <130 mEq/L were included for a four-week trial. At screening, patients underwent cognitive and HRQOL testing, serum/urine chemistries and companion burden assessment. Patients then underwent fluid restriction and diuretic withdrawal for two weeks after which cognitive tests were repeated. If Na was still <130 mEq/L, brain magnetic resonance imaging (MRI) was performed and tolvaptan was initiated for 14 days with frequent clinical/laboratory monitoring. After 14 days of tolvaptan, all tests were repeated. Comparisons were made between screen, pre- and post-drug periods Na, urine/serum laboratories, cognition, HRQOL and companion burden. Results: 24 cirrhotics were enrolled; seven normalized Na without tolvaptan with improvement in cognition. The remaining 17 received tolvaptan of which 14 completed the study over 13 +/- 2 days (age 58 +/- 6 years, MELD 17, 55% HCV, median 26 mg/day of tolvaptan). Serum Na and urine free water clearance increased with tolvaptan without changes in mental status or liver function. Cognitive function, HRQOL and companion burden only improved in these 14 patients after tolvaptan, along with reduced total brain and white matter volume, increase in choline on magnetic resonance spectroscopy, and reduced cytotoxic oedema. Conclusions: Short-term tolvaptan therapy is well tolerated in cirrhosis. Hyponatraemia correction is associated with cognitive, HRQOL, brain MRI and companion burden improvement. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 50 条
  • [1] Correction of Hyponatremia with Tolvaptan therapy is associated with Improved Cognition, Quality of Life, Reduced Caregiver Burden and Brain Edema on MRI in Cirrhosis
    Bajaj, Jasmohan S.
    Ahluwalia, Vishwadeep
    Gavis, Edith A.
    Feldman, George
    Unser, Ariel
    Noble, Nicole
    White, Melanie
    Monteith, Pamela
    Gilles, HoChong
    Thacker, Leroy
    Heuman, Douglas M.
    HEPATOLOGY, 2013, 58 : 876A - 876A
  • [2] Correction of hyponatraemia in cirrhosis: Treating more than a number!
    Cardenas, Andres
    Riggio, Oliviero
    JOURNAL OF HEPATOLOGY, 2015, 62 (01) : 13 - 14
  • [3] Inguinal hernioplasty improves the quality of life in patients with cirrhosis
    Patti, Rosalia
    Almasio, Piero Luigi
    Buscemi, Salvatore
    Fama, Fausto
    Craxi, Antonio
    Di Vita, Gaetano
    AMERICAN JOURNAL OF SURGERY, 2008, 196 (03): : 373 - 378
  • [4] COGNITION AND QUALITY OF LIFE IN PATIENTS WITH BRAIN TUMORS
    Casarotti, A.
    Bello, L.
    Comi, A.
    Fava, E.
    Papagno, C.
    NEURO-ONCOLOGY, 2010, 12 : 26 - 26
  • [5] Supportive care, cognition and quality of life in brain metastases
    Le Rhun, E.
    Taillibert, S.
    Blonski, M.
    Delbez, N. Jouniaux
    Delgadillo, D.
    Taillia, H.
    Auquier, P.
    Belin, C.
    Bonnetain, F.
    Varin, D.
    Tallet, A.
    Taillandier, L.
    CANCER RADIOTHERAPIE, 2015, 19 (01): : 55 - 60
  • [6] Patient Reported Outcomes Assessment improves Quality of Life in Patients with Cirrhosis
    Verma, Manisha
    Navarro, Victor J.
    Stites, Shana
    HEPATOLOGY, 2017, 66 : 394A - 395A
  • [7] An integrated care pathway improves quality of life in Primary Biliary Cirrhosis
    Jones, David E. J.
    Sutcliffe, Katy
    Pairman, Jessie
    Wilton, Katharine
    Newton, Julia L.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2008, 101 (07) : 535 - 543
  • [8] Brain Tumor at Diagnosis: From Cognition and Behavior to Quality of Life
    Chieffo, Daniela Pia Rosaria
    Lino, Federica
    Ferrarese, Daniele
    Belella, Daniela
    Della Pepa, Giuseppe Maria
    Doglietto, Francesco
    DIAGNOSTICS, 2023, 13 (03)
  • [9] Surgical correction of primary hyperparathyroidism improves quality of life - Discussion
    Cady, B
    Burney, RE
    Carty, SE
    Pasieka, JL
    Clark, OH
    SURGERY, 1998, 124 (06) : 991 - 992
  • [10] Wellness intervention improves quality of life and cognition in persons with early Multiple Sclerosis
    Giesser, Barbara
    Rapozo, Molly K.
    Glatt, Ryan
    Patis, Corwin
    Panos, Stella
    Merrill, David A.
    Siddarth, Prabha
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1033 - 1033